Skip to main content
Pancreatic oncology

Pancreatic Cancer

Resectability, Whipple, distal pancreatectomy, and systemic therapy

Resectability language (resectable / borderline / locally advanced) matters more than catchy procedure names.

The Whipple name scares everyone; resectability depends on vessel involvement, not the procedure label. I review contrast imaging before promising surgery. Jaundice with weight loss needs prompt work-up — do not assume gallstones alone. Pancreatic adenocarcinoma requires tumor-board input and an honest resectability discussion. Whipple and distal pancreatectomy are offered only when oncologically and medically appropriate. Nutrition, biliary drainage, and performance status are optimized before any large resection.

Pancreatic Cancer
  • Labeled on this figure: Pancreas, Duodenum, Head, Body and Tail.
  • Related figures on this page: Anatomy, Diagnosis, Tumor location, Whipple, Distal pancreatectomy.

Educational figures

Tap a figure to enlarge. These English illustrations mirror the Turkish hub gallery for this condition.

  • Anatomy
  • Diagnosis
  • Tumor location
  • Whipple
  • Distal pancreatectomy

What to know

  • Why timing is critical

    Key note inside

    Jaundice, nutrition, cholangitis risk, and performance status must be optimized before major resection. Rushing an unfit patient into Whipple helps no one.

  • Not every mass is operable up front

    Borderline or locally advanced disease may need neoadjuvant therapy first. “Inoperable today” is not always “never operable.”

  • Whipple versus distal

    Head lesions may need pancreaticoduodenectomy; body/tail lesions may need distal pancreatectomy. Names matter less than margins, vessels, and reconstruction plan.

  • Tumor board honesty

    Resectability calls are imaging- and experience-dependent. A second review at the tumor board is appropriate when categories disagree.

  • After major pancreatectomy

    Pancreatic fistula risk, endocrine/exocrine insufficiency, and stepwise diet are expected discussion points — not surprises after discharge.

What happens next

Jaundice, pain, and other warning signs that need timely review

Oncologic surgery7 chapters

Scientific evidence atlas

Plain-language summaries of the key clinical trials behind current treatment decisions.

Evidence

Scientific sources

Show sources · 6

Core sources for pancreatic adenocarcinoma diagnosis, resectability, and systemic therapy framing. PRODIGE 24, PREOPANC, and NORPACT-1 are clinical trials — not guidelines.

  1. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upESMO · 2023 · DOI: 10.1016/j.annonc.2023.08.009Open source
  2. NCCN Guidelines — Pancreatic AdenocarcinomaNCCN · Current versionOpen source
  3. PRODIGE 24 / CCTG PA.6 — FOLFIRINOX versus gemcitabine after resection of pancreatic cancer (RCT)NEJM (clinical study; not a guideline) · 2018 · DOI: 10.1056/NEJMoa1809775Open source
  4. PREOPANC — Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer (RCT)Journal of Clinical Oncology (clinical study; not a guideline) · 2022 · DOI: 10.1200/JCO.21.02233Open source
  5. NORPACT-1 — Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (RCT)Lancet Gastroenterology & Hepatology (clinical study; not a guideline) · 2024 · DOI: 10.1016/S2468-1253(23)00405-3Open source
  6. ESMO Gastrointestinal Cancer GuidelinesESMO · Living / eUpdateOpen source

Source list last checked: 21 August 2026. (Page content review date may appear separately above.)

Appointment / info

Bring recent contrast CT/MRI discs for resectability review — reports alone are often not enough.

This page is for education. It is not medical advice and does not replace a visit with your physician.

Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · English patient-education hub.